Sunbird Bio, a Cambridge, MA-based biotechnology company developing proprietary blood-based technologies, raised additional $14M in funding.
The round was led by Eli Lilly and Company and EDBI, as well as continued participation from existing investors ClavystBio, Polaris Partners and S32.
The company intends to use the funds to expand the clinical development of its proprietary blood-based diagnostic platform that has demonstrated potential to support earlier, more accurate diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease and other neurological disorders.
Led by CEO John McDonough, Sunbird Bio has developed a blood-based diagnostic platform that has demonstrated the ability to accurately and directly detect and monitor very low levels of disease-specific proteins, including amyloid beta (Aβ), tau and alpha synuclein (α-synuclein), that aggregate in the brain and play a key role in the pathogenesis of Alzheimer’s disease, Parkinson’s disease and other neurological disorders. Due to the proprietary design of the platform, it has the capability to add assays to the platform as research continues to uncover new protein biomarkers that signal the presence of neurological diseases. This innovation creates the potential for Sunbird Bio to empower researchers and clinicians with the broadest panel of diagnostics that will deliver unparalleled insights not readily available from current tests.
The company plans to open new laboratory space and initiate additional clinical studies of its diagnostic technology by early 2025. Sunbird Bio, which is jointly headquartered in Cambridge, Massachusetts and Singapore, is actively securing partnerships with biopharma companies and others to accelerate the development of its diagnostic platform and conduct clinical studies. Use cases include patient enrollment, longitudinal monitoring, patient stratification and target engagement.
FinSMEs
16/10/2024